Viral Reactivation in Haploidentical Transplants Using Post-Transplantation Cyclophosphamide – a Single Institution Experience  Reshma Ramlal, MD, Koji Sasaki, MD, Sara Lozano Cerrada, MD, Samer A. Srour, MD, Julianne Chen, BS, R. Gabriella Rondon, MD, Katy Rezvani, MD, Betul Oran, MD, Amanda Olson, M.D., Elizabeth J. Shpall, MD, Richard E. Champlin, MD, Stefan O. Ciurea, MD  Biology of Blood and Marrow Transplantation  Volume 22, Issue 3, Pages S375-S376 (March 2016) DOI: 10.1016/j.bbmt.2015.11.887 Copyright © 2016 Terms and Conditions

Figure 1 a) Overall survival, b) progression-free survival, c) cumulative incidence of CMV reactivation, d) cumulative incidence of CMV reactivation by serology, e) cumulative incidence of BKV reactivation f) cumulative incidence of acute GVHD, g) cell count at D30-60 and D90. Biology of Blood and Marrow Transplantation 2016 22, S375-S376DOI: (10.1016/j.bbmt.2015.11.887) Copyright © 2016 Terms and Conditions